Mechanism of Action
Heqet Therapeutics pipeline compounds efficiently target multiple pathways via the upregulation of certain non-coding RNAs. These include two factors in the Hippo pathway, the upstream inhibitory TAO kinase 1 (TAOK1) and the phospho-YAP E3 ubiquitin-ligase β-transducing repeat containing protein (β-TrCP)15, and the actin cytoskeleton regulatory protein cofilin-216.
Publications
Eulalio, A., Mano, M., Dal Ferro, M., Zentilin, L., Sinagra, G., Zacchigna, S., & Giacca, M. (2012). Functional screening identifies miRNAs inducing cardiac regeneration. Nature, 492(7429), 376-381.
Gabisonia, K., Prosdocimo, G., Aquaro, G. D., Carlucci, L., Zentilin, L., Secco, I., … & Giacca, M. (2019). MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs. Nature, 569(7756), 418-422.
Giacca, M. (2020). Cardiac regeneration after myocardial infarction: an approachable goal. Current Cardiology Reports, 22(10), 1-8.
Braga, L., Ali, H., Secco, I., & Giacca, M. (2021). Non-coding RNA therapeutics for cardiac regeneration. Cardiovascular research, 117(3), 674-693.